Dr. Reddy's, Takeda Pharma ink pact to distribute India's first dengue vaccine QDENGA
Must read — 2 past UPSC questions on this theme (Prelims GS-1 2017, Mains GS-3 2021).
2-minute summary
Dr. Reddy's Laboratories has entered into an exclusive partnership with Japan's Takeda Pharmaceutical Company to distribute QDENGA, India's first approved dengue vaccine, in the country's private market. Approved by the Central Drugs Standard Control Organization (CDSCO) in July 2026 for individuals aged 4 to 60 years, QDENGA is a live-attenuated tetravalent vaccine designed to provide broad immune coverage against all four dengue virus serotypes (DENV-1 to DENV-4). It is administered as a two-dose regimen, three months apart. Under the agreement, Dr. Reddy's will handle private-market distribution, disease awareness, and healthcare professional engagement, while Takeda retains public-market rights, legal ownership, and overall medical and brand oversight. The vaccine, already distributed globally with over 32 million doses across 43 countries, is expected to become available in India in the first half of 2027, subject to local regulatory processes.
Why it's in the news
Dr. Reddy's and Takeda Pharmaceutical have signed an exclusive agreement to distribute QDENGA, India's first approved dengue vaccine, in the private market, with an expected launch in the first half of 2027.
Facts to remember
- Dr. Reddy's Laboratories entered into an exclusive partnership with Japan's Takeda Pharmaceutical Company to distribute QDENGA in India's private market.
- QDENGA is India's first approved dengue vaccine, approved by the CDSCO in July 2026 for individuals aged 4 to 60 years.
- It is a live-attenuated tetravalent vaccine designed to provide broad immune coverage against all four dengue virus serotypes (DENV-1 to DENV-4).
- The vaccine is administered as a two-dose regimen, three months apart.
- Globally, the vaccine has been distributed with over 32 million doses across 43 countries.
Background and context
Dengue is a major vector-borne public health challenge in India, transmitted primarily by the Aedes aegypti mosquito. The disease is caused by the dengue virus (DENV), which has four distinct serotypes (DENV-1, DENV-2, DENV-3, and DENV-4). Developing an effective vaccine has historically been challenging because partial immunity to one serotype can lead to severe dengue upon subsequent infection with a different serotype—a phenomenon known as Antibody-Dependent Enhancement (ADE). Therefore, a viable vaccine must be tetravalent, providing balanced protection against all four strains simultaneously. QDENGA (TAK-003), developed by Takeda, addresses this by using a live-attenuated DENV-2 virus strain as the genetic backbone, engineered to express surface proteins of all four serotypes. Its approval in India marks a significant shift from purely vector-control strategies to active immunization.
Constitutional provisions
- Article 47 — Directs the State to regard the raising of the level of nutrition and the standard of living of its people and the improvement of public health as among its primary duties.
- Seventh Schedule (List II, Entry 6) — Public health and sanitation; hospitals and dispensaries fall under the State List, making state-level execution of vaccination drives crucial.
- Seventh Schedule (List III, Entry 29) — Prevention of the extension from one State to another of infectious or contagious diseases or pests falls under the Concurrent List, justifying Central interventions and regulatory approvals.
Committees and reports
- National Health Policy (NHP) 2017 — Advocates for reducing the disease burden of vector-borne diseases and highlights the role of immunization and public-private partnerships in achieving universal health coverage.
Government schemes
- National Vector Borne Disease Control Programme (NVBDCP) — The central nodal agency for the prevention and control of vector-borne diseases in India, including dengue, malaria, and chikungunya.
International organisations
- World Health Organization (WHO) — Provides global guidelines on dengue prevention, vector control, and vaccine prequalification, recommending dengue vaccines in highly endemic areas.
Previous UPSC questions on this theme
- Prelims GS-1 2017 — Consider the following statements: 1. In tropical regions, Zika virus disease is transmitted by the same mosquito that transmits dengue. 2. Sexual transmission of Zika virus disease is possible. Which of the statements given above is/are correct? (a) 1 only (b) 2 only (c) Both 1 and 2 (d) Neither 1 nor 2
- Mains GS-3 2021 — What are the research and developmental achievements in applied biotechnology? How will these achievements help to uplift the poorer sections of the society?
Mains practice: Analyze the public health challenges posed by the co-circulation of multiple dengue virus serotypes in India. How can the introduction of tetravalent vaccines transform India's vector-borne disease management?
Dengue presents a severe public health challenge in India, with thousands of cases reported annually across both urban and rural landscapes. The complexity of managing dengue is compounded by the co-circulation of all four dengue virus serotypes (DENV-1 to DENV-4).
**Public Health Challenges of Co-circulating Serotypes:**
• **Antibody-Dependent Enhancement (ADE):** Primary infection with one serotype provides lifelong immunity to that specific strain but only temporary, partial protection against others. Subsequent infections with a different serotype significantly increase the risk of severe dengue, such as Dengue Hemorrhagic Fever (DHF) or Dengue Shock Syndrome (DSS), due to ADE.
• **Diagnostic and Clinical Burden:** Co-circulation makes clinical management difficult, as different strains can exhibit varying severity, requiring robust diagnostic infrastructure that is often lacking in rural areas.
• **Inadequacy of Traditional Vector Control:** Traditional methods like chemical fogging and source reduction are reactive and resource-intensive, failing to curb transmission effectively during peak monsoon seasons.
**Transformative Role of Tetravalent Vaccines (like QDENGA):**
• **Broad-Spectrum Immunity:** Being a live-attenuated tetravalent vaccine, QDENGA triggers an immune response against all four serotypes simultaneously, mitigating the risk of ADE associated with single-strain exposure.
• **Reduction in Hospitalization:** By preventing severe disease manifestations, the vaccine can significantly reduce the seasonal burden on India's tertiary healthcare infrastructure.
• **Complementing Vector Control:** Vaccination shifts the strategy from reactive vector management to proactive, population-level active immunization, building herd immunity over time.
**Conclusion:**
While the introduction of India's first dengue vaccine is a landmark milestone, it must not be viewed as a standalone solution. To achieve sustained reduction in dengue morbidity, the vaccine rollout must be integrated with robust civic sanitation, active community participation in vector control, and equitable distribution models across both public and private healthcare sectors.
Prelims practice questions
Q1. With reference to the QDENGA vaccine recently in the news, consider the following statements: 1. It is India's first approved vaccine for dengue. 2. It is a live-attenuated tetravalent vaccine designed to target all four dengue virus serotypes. 3. The vaccine is administered as a single-dose regimen to ensure lifelong immunity. Which of the statements given above are correct?
- 1 and 2 only
- 2 and 3 only
- 1 and 3 only
- 1, 2 and 3
Answer: A. Statements 1 and 2 are correct. QDENGA is India's first approved dengue vaccine and is a live-attenuated tetravalent vaccine targeting DENV-1 to DENV-4. Statement 3 is incorrect because it is administered as a two-dose regimen given three months apart, not as a single-dose regimen.
Q2. Which of the following statements is/are correct regarding the transmission and biology of the Dengue virus? 1. Dengue is transmitted to humans through the bites of infected female Anopheles mosquitoes. 2. Infection with one dengue serotype provides lifelong immunity against all other serotypes due to cross-reactivity. Select the correct answer using the code given below:
- 1 only
- 2 only
- Both 1 and 2
- Neither 1 nor 2
Answer: D. Both statements are incorrect. Dengue is transmitted primarily by female Aedes aegypti mosquitoes (not Anopheles). Infection with one serotype provides lifelong immunity only against that specific serotype, while subsequent infections with other serotypes increase the risk of severe dengue due to antibody-dependent enhancement.
Q3. In India, which authority is responsible for granting marketing authorization and regulatory approvals for vaccines and new drugs?
- National Centre for Disease Control (NCDC)
- Central Drugs Standard Control Organization (CDSCO)
- Indian Council of Medical Research (ICMR)
- Department of Biotechnology (DBT)
Answer: B. The Central Drugs Standard Control Organization (CDSCO), headed by the Drugs Controller General of India (DCGI), is the national regulatory body responsible for approving new drugs, clinical trials, and vaccines in India.
Revision flashcards
- What type of vaccine technology is used in QDENGA? It is a live-attenuated tetravalent vaccine, which uses weakened virus strains to stimulate immune responses against all four dengue serotypes (DENV-1 to DENV-4).
- What is the approved age group for QDENGA in India as per the CDSCO authorization? It is approved for individuals aged 4 to 60 years.
- What is the prescribed dosage regimen for the QDENGA vaccine? A two-dose regimen administered three months apart.
- Which mosquito species is the primary vector for the transmission of the dengue virus? Aedes aegypti (and to a lesser extent, Aedes albopictus).
- How are the distribution rights for QDENGA split between Dr. Reddy's and Takeda in India? Dr. Reddy's exclusively manages private-market distribution and disease awareness, while Takeda retains public-market rights, legal ownership, and overall medical/brand oversight.